William Towner to Aged
This is a "connection" page, showing publications William Towner has written about Aged.
Connection Strength
0.337
-
Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
Score: 0.040
-
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
Score: 0.021
-
Effect of Physical Activity Coaching on Acute Care and Survival Among Patients With Chronic Obstructive Pulmonary Disease: A Pragmatic Randomized Clinical Trial. JAMA Netw Open. 2019 08 02; 2(8):e199657.
Score: 0.020
-
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017 05; 18(3):118-125.
Score: 0.017
-
Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017 04 24; 31(7):989-993.
Score: 0.017
-
Examining HIV Viral Load in a Matched Cohort of HIV Positive Individuals With and Without Psoriasis. J Drugs Dermatol. 2017 Apr 01; 16(4):372-377.
Score: 0.017
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Score: 0.016
-
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31; 373(27):2599-607.
Score: 0.016
-
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):818-26.
Score: 0.015
-
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):809-17.
Score: 0.015
-
Patient-centered physical activity coaching in COPD (Walk On!): A study protocol for a pragmatic randomized controlled trial. Contemp Clin Trials. 2016 Jan; 46:18-29.
Score: 0.015
-
Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1167-73.
Score: 0.015
-
Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015 Apr 15; 60(8):1278-80.
Score: 0.015
-
HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
Score: 0.014
-
Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):495-502.
Score: 0.014
-
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 01; 384(9954):1597-605.
Score: 0.014
-
Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
Score: 0.014
-
Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
Score: 0.012
-
Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
Score: 0.011
-
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008 May-Jun; 9(3):152-63.
Score: 0.009
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
Score: 0.009